// Account brief

Sanofi

Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source.

Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.

Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.

Scores

Theme Priority (1 to 10) Delivery (0 to 10) Stage Commitments made public, last 12 months R&D roles open on 6 Oct 2026
AI in drug discovery 6 6 scaled 6 3
Research labs and data No eligible company disclosure identified No eligible company disclosure identified 0 1

The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.

Summary

Sanofi calls itself an AI-powered biopharma company, and AI in drug discovery scores 6 out of 10 for priority and 6 for delivery, at the scaled stage. Its annual filing says AI and machine learning now support all small and large molecule drug design, doubling research teams' molecular throughput, and that 90% of pipeline targets are credentialed with its data and AI systems. Six AI in drug discovery commitments were made public in the last 12 months, including a new Computational and AI Strategy function in R&D, the Owkin K Pro agent collaboration, the Earendil Labs antibody collaboration and an expanded Aqemia collaboration, and four in the year before. For research labs and data, no eligible company disclosure was identified; Sanofi's robotic and AI work in its CMC development lab is process development, which the radar groups with manufacturing and excludes. On 6 October 2026 Sanofi had 3 R&D roles open in AI in drug discovery, including a Head of Agentic Biology, and 1 in research labs and data, a Principal Automation Software Engineer.

AI in drug discovery

What the company says: Priority 6

3) Accelerate efficiency ... AI and data science are already supporting our teams in areas such as accelerating drug discovery

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28

organized around four key priorities: 1) focus on growth; 2) lead with innovation; 3) accelerate efficiency; and 4) reinvent how we work

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 27

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and creating compelling growth.

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 26

Matt Truppo ... Head of research platforms and computational R&D

Year-end late-stage pipeline review (investor presentation), 16 Dec 2025, p. 4

Matt Truppo, Global Head of Computational and AI Strategy at Sanofi R&D, spoke with Najat Khan

Partner Spotlight: How Sanofi and Recursion are reimagining drug discovery with AI, 29 Jun 2026

Digital Transformation and Artificial Intelligence (Delivery of AI agenda in R&D and commercial operations, development of a data strategy) 7.5%

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 132

40% based on specific individual objectives: Portfolio & Assets (7.5%); Digital Transformation and Artificial Intelligence (7.5%)

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 127

What it shows running: Delivery 6, scaled

Digital ... In R&D: ... 90% targets in the pipeline now being credentialed using our data and AI systems

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 137

100% small and large molecule drug design efforts now supported by AI/ML methods, doubling molecular throughput of research teams

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 137

our Target Discovery engines have delivered seven novel drug targets in just one year

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28

in research, we have built multiple AI programs seeking to reduce research lead-times through improved predictive modelling and automated time-sink activities

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28

Computational models developed by Sanofi’s “Target, Diseases and System Biology” (TDSB) team help narrow an initial list that might include hundreds of possible targets down to a workable set.

Dual-Targeting Library: designing novel bispecific therapeutics, 28 Jul 2026

Sanofi scientists are using Artificial Intelligence (AI) to design better viral

How Sanofi is rewriting the script for untreated rare diseases, 30 Jun 2026

AI is helping our scientists by supporting faster identification of the right targets ... and collaborating to efficiently design molecules in silico for specific targets

AI Across the R&D Value Chain: Portfolio Decision-Making, 24 Feb 2026

Our R&D teams are already accelerating their work: our Target Discovery engines have delivered seven novel drug targets in just one year.

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28

Initial results suggest potential improvements in target identification efficiency in therapeutic areas like immunology, oncology and neurology, though actual results may vary and are subject to ongoing validation

Sanofi Annual Report on Form 20-F 2025, 17 Feb 2026, p. 28

Commitments made public in the last 12 months: 6

Commitments made public in the year before: 4

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 3

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Research labs and data

No eligible company disclosure identified for this theme in the reviewed sources and period. This is not a finding that the company is inactive.

Commitments made public in the last 12 months: 0

None identified in the reviewed sources.

Commitments made public in the year before: 0

None identified in the reviewed sources.

Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.

R&D roles open on 6 October 2026: 1

  • Principal Automation Software Engineer, Framingham, United States of America, posting since closed

These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.

Two questions to investigate (Ortent's interpretation)

  1. Sanofi's new Computational and AI Strategy function has a Head of Agentic Biology who is to evaluate and onboard AI vendors, the Owkin deal was announced by the Chief Digital Officer, and partnering and business development now sit under Finance. Who decides whether to license an external AI discovery tool or build one, and which buying route does such a licence follow?
  2. Lab automation and lab data work sits in several units, from a Bioanalytics Automation Lab that links robots to LIMS and ELN to a large molecules research organisation that a Genedata page says uses Genedata Biologics. Who owns lab automation and lab informatics decisions in research, and how do these units work with the Computational and AI Strategy function, the R&D Digital Accelerator and the Digital function?

Coverage limits

The web search budget ran out, and a later top-up of searches filled only some gaps, so partner newswires, consortium and academic sources remain partly searched in both themes. Business Wire, GlobeNewswire, Fierce Biotech, SEC EDGAR and Recursion's investor site blocked access and GitHub could not be checked, so partner releases were read through copies and Recursion milestones after February 2026 are unchecked. Results-call transcripts were missing for several quarters, and the Sanofi Digital and AI page is undated. Coverage differs between the two years, so the commitment counts for the last 12 months and the year before are not a like-for-like comparison.

// GET IN TOUCH

Clarity when it counts.

For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.

Request a 30-minute intro call